TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News Ovid Therapeutics (NASDAQ: OVID) surges 28% on $175m private placement: What does it mean for biotech investors? Ovid Therapeutics (NASDAQ: OVID) jumped 28% after securing $175M via a PIPE deal. Explore its pipeline focus, stock sentiment, and investor outlook. byPallavi MadhirajuOctober 3, 2025